SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)

Gómez-España, Ma A.; Montes, Ana; Garcia-Carbonero, Rocío; Mercadé, T. Macarulla; Maurel, Joan; Martín, A. Muñoz; Pazo‐Cid, Roberto; Vera, Ruth; Carrato, Alfredo; Feliú, Jaime

doi:10.1007/s12094-021-02573-1

Cited by 34 publications

(19 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pancreatic cancer is one of the most common clinical tumors [31]. Early diagnosis is difficult, and comprehensive treatment based on surgery does not improve the survival time and quality of life of patients after surgery [32]. This study found that in human pancreatic cancer tissues, hsa_circ_0074298 comprised 1,486 bp and was produced by splicing parts of exons of the HARS gene.…”

Section: Discussionmentioning

confidence: 97%

Hsa_circ_0074298 promotes pancreatic cancer progression and resistance to gemcitabine by sponging miR-519 to target SMOC

Chen¹,

Wang²,

Xie³

et al. 2022

J. Cancer

View full text Add to dashboard Cite

Objective: To investigate the expression of hsa_circ_0074298 (circular RNA) and the molecular mechanism that promotes tumor growth and enhances the chemoresistance of pancreatic cancer. Methods: Real-time reverse transcription-PCR was used to detect hsa_circ_0074298 expression in pancreatic cancer. The intracellular localization of hsa_circ_0074298 was determined by RNA in situ hybridization. The CCK8 method, colony formation assay, Transwell assay, and flow cytometry were used to evaluate the effects of hsa_circ_0074298 on the proliferation, migration, invasion, cell cycle, apoptosis of pancreatic cancer cells. Bioinformatics analysis and dual luciferase assays were employed to detect the association of hsa_circ_0074298 and miR-519d and the binding of miR-519d to the target gene SMOC2. A subcutaneous xenograft model was established to observe the effect of hsa_circ_0074298 in vivo. Results: The hsa_circ_0074298 was mainly localized in the cytoplasm. Hsa_circ_0074298 was highly expressed in pancreatic cancer tissues and cell lines. The expression of hsa_circ_0074298 was significantly correlated with pancreatic cancer tumor size, lymph node metastasis, and pathological grade. hsa_circ_0074298 could sponge miR-519, and miR-519d bound to SMOC2. Downregulation of hsa_circ_0074298 expression significantly inhibited cell proliferation, migration, invasion, colony forming ability and promoted cell cycle arrest, apoptosis and chemo-resistance of pancreatic cancer in vitro and vivo. However, the effects could be reversed by a miR-519d inhibitor or SMOC2 overexpression. Conclusion: By sponging miR-519 and targeting SMOC2, hsa_circ_0074298 promotes the growth and metastasis of pancreatic cancer and increases the resistance of pancreatic cancer cells to gemcitabine.

show abstract

Section: Discussionmentioning

confidence: 97%

Hsa_circ_0074298 promotes pancreatic cancer progression and resistance to gemcitabine by sponging miR-519 to target SMOC

Chen¹,

Wang²,

Xie³

et al. 2022

J. Cancer

View full text Add to dashboard Cite

show abstract

“…These highly selected patients often benefit from surgical treatment. A unified standard of the indications for surgical treatment of multifocal iCCA is lacking among other guidelines [ 11 , 17 , 18 , 19 , 20 , 21 ]. As a result, the surgical treatment rate of T2mN0M0 is much lower than that of T2sN0M0.…”

Section: Discussionmentioning

confidence: 99%

Validation of the Prognostic Role for Surgical Treatment in Stage II Intrahepatic Cholangiocarcinoma: A SEER Population-Based Study

Luo

et al. 2023

JCM

View full text Add to dashboard Cite

Background: This study aimed to determine the role of surgical treatment in patients with stage II intrahepatic cholangiocarcinoma (iCCA). Methods: Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We divided stage II iCCAs into solitary tumors with vascular invasion (T2sN0M0) and multiple tumors with/without vascular invasion (T2mN0M0) according to the criteria of AJCC v.8. The Kaplan–Meier method and log-rank test were used to evaluate differences in overall survival (OS). We performed two propensity score-matching analyses with (PSM2) or without (PSM1) surgical treatment. Results: 667 and 778 iCCA patients with stage II and IIIB were recruited. After PSM2, there was no survival difference in stage II iCCA patients in hypothetical conditions with similar surgical proportions (p = 0.079). However, OS was significantly worse in patients with T2mN0M0 than T2sN0M0 when the actual surgical proportion existed after PSM1 (p < 0.001). OS was similar between T2mN0M0 and IIIB regardless of whether PSM1 (p = 0.907) or PSM2 (p = 0.699) was performed. The surgical treatment was verified to associate with prognosis. Conclusions: The survival benefit by surgical treatment was existed in Stage II but not in Stage IIIB iCCA patients. The OS for T2mN0M0 will approach that of T2sN0M0 if the surgical proportion is gradually increased.

show abstract

“…To date, most guidelines for GBC have recommended routine follow-up with a 3-month interval during the first 2 years after curative-intent therapy, and a 6-month interval thereafter, up to 5 years. 25 , 26 However, there is no research supporting a specific surveillance schedule for patients with GBC nor has there been any study focusing on the impact of regular follow-up on prognosis. The present study demonstrated that more than 80% of recurrence occurred within 29 months after resection (early recurrence), typically in a location distant from the primary tumor site.…”

Section: Discussionmentioning

confidence: 99%

Prediction of Early Recurrence After R0 Resection for Gallbladder Carcinoma of Stage T1b–T3

Peng¹,

Nie²,

Li³

et al. 2022

CMAR

View full text Add to dashboard Cite

The time-to-tumor recurrence can predict the prognosis of hepatobiliary cancers following curative-intent resection. Therefore, for patients with gallbladder carcinoma (GBC) of stage T1b-T3 who had undergone R0 resection, we investigated the risk factors for early recurrence of GBC and their prognosis. Patients and Methods: A total of 260 patients with GBC with T1b-T3 disease and an R0 margin were identified. Their clinicopathologic characteristics, perioperative details and prognostic data were reviewed. Survival analyses were carried out using the Kaplan-Meier method. Logistic regression models were used to identify the risk factors for early recurrence. Results:The optimal cutoff for early recurrence was 29 months. Early recurrence tended to result in relapse far from the primary tumor, and such patients tended to have significantly worse overall survival. Multivariate analysis revealed that T3 disease, N1/N2 stage, poor differentiation of tumor, and lymphovascular invasion (LI) were associated with a greater risk of early recurrence. Patients diagnosed as having GBC incidentally and who had the risk factors of early recurrence were more likely to benefit from re-resection 2-4 weeks after a cholecystectomy. Conclusion: T3 stage, N1-N2 stage, poor differentiation, and LI were independent risk factors associated with early recurrence for patients with GBC with stage T1b-T3 disease after R0 resection.

show abstract

SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)

Cited by 34 publications

References 57 publications

Hsa_circ_0074298 promotes pancreatic cancer progression and resistance to gemcitabine by sponging miR-519 to target SMOC

Hsa_circ_0074298 promotes pancreatic cancer progression and resistance to gemcitabine by sponging miR-519 to target SMOC

Validation of the Prognostic Role for Surgical Treatment in Stage II Intrahepatic Cholangiocarcinoma: A SEER Population-Based Study

Prediction of Early Recurrence After R0 Resection for Gallbladder Carcinoma of Stage T1b–T3

Contact Info

Product

Resources

About